Hannah M. Cheeseman

Imperial College London - Department of Infectious Disease

SCHOLARLY PAPERS

3

DOWNLOADS

1,676

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, University College London, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,561 (25,979)

Abstract:

Loading...

2.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University College London, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 60 (773,393)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response

3.

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Number of pages: 60 Posted: 19 Feb 2025
London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, Imperial College London - Department of Infectious Disease, Government of Uganda - Uganda Virus Research Institute (UVRI), London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, MRC/UVRI & LSHTM Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, London School of Hygiene & Tropical Medicine - Uganda Research Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease and London School of Hygiene & Tropical Medicine - Uganda Research Unit
Downloads 55 (807,671)

Abstract:

Loading...

Self-amplifying RNA (saRNA) vaccine, SARS-CoV-2 immunogenicity, COVID-19 Vaccination in Africa, Neutralising antibody responses, Spike-specific IgG antibodies, Vaccine safety and reactogenicity, Seronegative vs. seropositive immune response